Gerard Bos
CEO
CiMaas BV
The startup develops immunotherapy treatments that utilize patient-derived dendritic cells for a cancer vaccine and donor natural killer cells to enhance immune response against specific cancer types. This approach targets patients with cancers that are resistant to current therapies, minimizing severe side effects associated with traditional treatments.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$2.9MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops immunotherapy treatments that utilize patient-derived dendritic cells for a cancer vaccine and donor natural killer cells to enhance immune response against specific cancer types. This approach targets patients with cancers that are resistant to current therapies, minimizing severe side effects associated with traditional treatments.